RESUMO
AIM: To understand the risk of hypoglycaemia during Ramadan fasting by use of CGM, as well as to observe the Glycemic control and renal functions in patients with diabetes and chronic kidney disease stage 3 (CKD-3). METHOD: A prospective interventional study conducted in the Dubai Hospital, a tertiary care centre in the United Arab Emirates, during the month of Ramadan 1437 AH (Hijri), which corresponded to June 6th till July 5th, 2016. 25 patients with type 2 diabetes and stage 3 chronic kidney disease (CKD stage 3) were included in the study, who intended to fast during Ramadan. The aim was to observe the serum glucose level through 24â¯h FreeStyle Libre flash continuous glucose monitor (FSL-CGM). Most patients had three sensors during the study, covering an average three weeks during Ramadan and three weeks outside Ramadan (Sha'ban and shawal). We also monitored the change in, BP, HBA1c, kidney functions and BMI before and after Ramadan. RESULTS: This study included 25 adults with a mean age of 60 (±14â¯years). Fasting Ramadan did not result in any significant change in biophysical and biochemical profile of these patients. Data from FSL-CGM showed significantly longer duration (101.9⯱â¯119.1 Vs. 45.9⯱â¯47.6â¯min, pâ¯<â¯0.033) and more frequent hypoglycemic episodes (4.4⯱â¯4.7 Vs. 2.3⯱â¯3.0, pâ¯<â¯0.047) during Ramadan compared tonon-Ramadan respectively. The mean blood glucose readings were also significantly lower (70.7⯱â¯29.3 Vs.93.7⯱â¯57.9â¯mg/dl pâ¯<â¯0.011) during Ramadan compared to non -fasting period. The renal function mean⯱â¯SD (serum creatinine 1.48⯱â¯0.37, 1.44⯱â¯0.37 and eGFR, 49.0⯱â¯18.4, 48.9⯱â¯17.5 p 0.9) showed no significant change due to fasting. CONCLUSION: In patients with diabetes and CKD-stage 3 Ramadan fasting under close supervision and optimal diabetes care, was not associated with worsening of HBA1c and renal function. Patients had significantly more frequent and prolonged hypoglycemic episodes during Ramadan.
